Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IconICLR -3.15%90 3-Year EBITDA Growth Rate is -13.90% as of Jun. 2026. GuruFocus rates ICLR with a GF Score™ of 90/100 and a GF Value™ of $213.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Icon ranks worse than 80.24% on this metric.
During the past 12 months, Icon's average EBITDA Per Share Growth Rate was -31.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Icon was 52.90% per year. The lowest was -20.20% per year. And the median was 8.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Icon 3-Year EBITDA Growth Rate Related Terms
ICLR vs RVTY, CRL, MEDP: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Icon's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icon 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Icon's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Icon's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -13.90% mean?
Icon (ICLR) has a 3-Year EBITDA Growth Rate of -13.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Icon and its competitors. According to the industry distribution chart, Icon ranks #134 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 80.2%.
Is Icon's 3-Year EBITDA Growth Rate too high?
Icon's current 3-Year EBITDA Growth Rate is -13.90%. Based on the distribution chart, Icon ranks #134 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Icon has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Icon's 3-Year EBITDA Growth Rate compare to RVTY and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Icon ranks #134 out of 167 companies for 3-Year EBITDA Growth Rate. This places Icon in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Icon and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Icon's current 3-Year EBITDA Growth Rate is -13.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icon stock overvalued right now?
Based on GuruFocus' analysis, Icon (ICLR) is currently considered Modestly Undervalued. The stock's GF Value™ is $213.60, compared to a current price of $158.41 — trading 25.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -13.90%. Icon's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Icon (ICLR), the current 3-Year EBITDA Growth Rate is -13.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icon (ICLR) Overvalued in 2026?
Based on GuruFocus' analysis, Icon stock appears to be undervalued.
The current stock price of $158.41 is trading 25.8% below its estimated GF Value™ of $213.60.
GuruFocus considers Icon to be Modestly Undervalued.
Key valuation signals for ICLR:
3-Year EBITDA Growth Rate: -13.90%
GF Value™: $213.60 vs. price of $158.41 (25.8% below fair value)
No single metric tells the full story. See the ICLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
90GF Score
Get the complete analysis for ICLR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICLR has been successfully added to your 
